Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Phase 1 Terminated 6 enrolled Virginia Commonwealth University National Cancer Institute (NCI) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This phase 1 study was developed to identify recommended phase 2 doses (RP2Ds) of AR-42 and pazopanib when given in combination for subsequent clinical trials and may have potentially identified candidate pharmacodynamic and predictive biomarkers.

Timeline

Start: 2016-07-08
Primary completion: 2016-11-24
Completion: 2019-03-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AR-42	Small molecule	10 mg	Oral
Subject	AR-42	Small molecule	20 mg	Oral
Subject	AR-42	Small molecule	30 mg	Oral
Subject	AR-42	Small molecule	40 mg	Oral
Subject	Pazopanib	Small molecule	600 mg	Oral
Subject	Pazopanib	Small molecule	800 mg	Oral

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Summary

Timeline

Drugs

Indications